Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal–bolus treatment in people with Type 1 diabetes: 1–year results from a randomized clinical trial (BOOST® T1)
ConclusionsOnce‐daily treatment with IDegAsp and IAsp as bolus insulin for remaining meals was associated with significantly lower risk of nocturnal confirmed hypoglycaemia, improved glycaemic control and showed non‐inferiority compared with IDet+IAsp, the standard of care in Type 1 diabetes.This article is protected by copyright. All rights reserved. (Source: Diabetic Medicine)
Source: Diabetic Medicine - January 16, 2016 Category: Endocrinology Authors: I. B. Hirsch, E. Franek, H. Mersebach, L. Bardtrum, K. Hermansen Tags: Research Article Source Type: research
Effects of analogue insulin in multiple daily injection therapy of type 2 diabetes on postprandial glucose control and cardiac function compared to human insulin: a randomized controlled long-term study
Conclusions:
MDI with AI results in better postmeal glucose control compared to HI. The treatment with AI is associated with improved diastolic cardiac function.ClinicalTrials.gov (NTC00747409) (Source: Cardiovascular Diabetology)
Source: Cardiovascular Diabetology - January 16, 2016 Category: Cardiology Authors: Helene von BibraThorsten SiegmundIris KingreenMarkus RiemerTibor SchusterPetra-Maria Schumm-Draeger Source Type: research
The impact of basal insulin analogues on glucose variability in patients with type 2 diabetes undergoing renal replacement therapy for end-stage renal disease
Conclusions
Insulin-resistant patients with type 2 diabetes undergoing hemodialysis for end-stage renal disease on insulin detemir exhibit lower glycemic variability and pro-inflammatory profile than with insulin glargine. (Source: International Urology and Nephrology)
Source: International Urology and Nephrology - January 2, 2016 Category: Urology & Nephrology Source Type: research
Review of Clinical Profile of IDegAsp.
Authors: Unnikrishnan AG, Singh AK, Modi KD, Saboo B, Garcha SC, Rao PV
Abstract
In patients with diabetes, treatment intensification requires basal and bolus insulin injections to control the fasting and prandial insulin needs. To overcome the burden of multiple daily injections, co-formulating basal and bolus insulins in single injection could allow a simple regimen with fewer injections. Current premixed insulin analogues are limited by the protaminated insulin component, which cannot provide effective basal coverage. While, long-acting insulin analogues like insulin glargine and insulin detemir cannot ...
Source: Journal of the Association of Physicians of India - December 20, 2015 Category: Journals (General) Tags: J Assoc Physicians India Source Type: research
Intranasal Insulin Improves Age-Related Cognitive Deficits and Reverses Electrophysiological Correlates of Brain Aging
Peripheral insulin resistance is a key component of metabolic syndrome associated with obesity, dyslipidemia, hypertension, and type 2 diabetes. While the impact of insulin resistance is well recognized in the periphery, it is also becoming apparent in the brain. Recent studies suggest that insulin resistance may be a factor in brain aging and Alzheimer’s disease (AD) whereby intranasal insulin therapy, which delivers insulin to the brain, improves cognition and memory in AD patients. Here, we tested a clinically relevant delivery method to determine the impact of two forms of insulin, short-acting insulin lispro (Hu...
Source: Journals of Gerontology Series A: Biological Sciences and Medical Sciences - December 16, 2015 Category: Geriatrics Authors: Maimaiti, S., Anderson, K. L., DeMoll, C., Brewer, L. D., Rauh, B. A., Gant, J. C., Blalock, E. M., Porter, N. M., Thibault, O. Tags: Original Article Source Type: research
Insulin detemir may be less efficacious in patients with nonalcoholic fatty liver disease and hypertriglyceridemia
We describe a relative lack of effectiveness of detemir in patients with significant NAFLD and hypertriglyceridemia, compared to isophane insulin. This may affect how such patients are managed with insulin.
Insulin detemir is commonly used in obese patients with diabetes mellitus as it is considered hepatoselective and causes less weight gain. We describe a relative lack of effectiveness of detemir in patients with significant NAFLD and hypertriglyceridemia, compared to isophane insulin. This may affect how such patients are managed with insulin. (Source: Clinical Case Reports)
Source: Clinical Case Reports - December 1, 2015 Category: Journals (General) Authors: Martin Whyte, Alberto Quaglia, David Hopkins Tags: Case Report Source Type: research
Long-acting Insulin Analog Detemir Displays Reduced Effects on Adipocyte Differentiation of Human Subcutaneous and Visceral Adipose Stem Cells
Since treatment with insulin detemir results in a lower weight gain compared to human insulin, we investigated whether detemir is associated with lower ability to promote adipogenesis and/or lipogenesis in human adipose stem cells (ASC). (Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD)
Source: Nutrition, Metabolism, and Cardiovascular Diseases : NMCD - November 30, 2015 Category: Nutrition Authors: Angelo Cignarelli, Sebastio Perrini, Pasquale Nigro, Romina Ficarella, Maria Barbaro, Alessandro Peschechera, Stefania Porro, Annalisa Natalicchio, Luigi Laviola, Franco Puglisi, Francesco Giorgino Source Type: research
Long-acting Insulin Analog Detemir Displays Reduced Effects on Adipocyte Differentiation of Human Subcutaneous and Visceral Adipose Stem Cells
Conclusion Insulin detemir displays reduced induction of the Pparg2 adipocyte master gene and diminished effects on adipocyte differentiation and lipogenesis in human subcutaneous and visceral ASC, in spite of normal activation of proximal insulin signaling reactions. These characteristics of insulin detemir may be of potential relevance to its weight-sparing effects observed in the clinical setting. (Source: Nutrition, Metabolism and Cardiovascular Diseases)
Source: Nutrition, Metabolism and Cardiovascular Diseases - November 30, 2015 Category: Nutrition Source Type: research
Detemir as a once-daily basal insulin in type 2 diabetes.
CONCLUSION: Results from PK/PD, observational, and controlled clinical studies support a once-daily detemir regimen alone or in combination with a prandial insulin or oral antidiabetes drugs.
PMID: 22287854 [PubMed] (Source: Clinical Pharmacology: Advances and Applications)
Source: Clinical Pharmacology: Advances and Applications - November 29, 2015 Category: Allergy & Immunology Tags: Clin Pharmacol Source Type: research
[Comparative analysis of insulin glargine vs. insulin detemir: A cost-minimization study applicable to Colombia].
CONCLUSIONS: As only medication costs are considered, differences in insulin units between IG and ID result in a differential cost in favor of IG that makes it a cost/effective alternative.
PMID: 26535542 [PubMed - in process] (Source: Biomedica : Revista del Instituto Nacional de Salud)
Source: Biomedica : Revista del Instituto Nacional de Salud - November 28, 2015 Category: Global & Universal Tags: Biomedica Source Type: research
Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
Conclusion
IDet was a cost-effective alternative to NPH insulin in the first year of treatment of patients with T1DM and patients with T2DM in Spain, with ICERs under the threshold value commonly accepted in Spain (€30,000/QALY).
Funding
Novo Nordisk. (Source: Diabetes Therapy)
Source: Diabetes Therapy - November 20, 2015 Category: Endocrinology Source Type: research
Safety and effectiveness of insulin detemir in combination with oral antidiabetic agents in an outpatient specialist setting: results of the Italian SOLVE™ observational study.
CONCLUSION: In the Italian outpatient setting, once-daily insulin detemir as add-on therapy to OADs was associated with a favourable tolerability profile. The improvement of the glycemic control after initiation with insulin detemir was clinically significant and did not cause an increase in body weight or hypoglycemia.
PMID: 26551483 [PubMed - in process] (Source: Minerva Endocrinologica)
Source: Minerva Endocrinologica - November 11, 2015 Category: Endocrinology Tags: Minerva Endocrinol Source Type: research
The Long-Term Cost-Effectiveness of Twice-Daily Exenatide with Insulin Glargine Versus Once-Daily Liraglutide with Insuline Detemir in Adult Patients with Type 2 Diabetes in Russia
to assess the cost-effectiveness of twice daily (TD) 10 μg exenatide with insulin glargine (EXE) vs once-daily (QD) liraglutide 1.2 mg or 1.8 mg both with insulin detemir (LIRA 1.2 or LIRA 1.8) in patients with type 2 diabetes mellitus (T2DM). (Source: Value in Health)
Source: Value in Health - October 23, 2015 Category: Global & Universal Authors: I Krysanov, M Tiapkina Source Type: research
Insulin degludec and insulin aspart: novel insulins for the management of diabetes mellitus
Patients with type 2 diabetes mellitus require insulin as disease progresses to attain or maintain glycaemic targets. Basal insulin is commonly prescribed initially, alone or with one or more rapid-acting prandial insulin doses, to limit mealtime glucose excursions (a basal–bolus regimen). Both patients and physicians must balance the advantages of improved glycaemic control with the risk of hypoglycaemia and increasing regimen complexity. The rapid-acting insulin analogues (insulin aspart, insulin lispro and insulin glulisine) all have similar pharmacokinetic and pharmacodynamic characteristics and clinical efficacy...
Source: Therapeutic Advances in Chronic Disease - October 13, 2015 Category: Internal Medicine Authors: Atkin, S., Javed, Z., Fulcher, G. Tags: Reviews Source Type: research
The past, present, and future of basal insulins
This article is protected by copyright. All rights reserved. (Source: Diabetes/Metabolism Research and Reviews)
Source: Diabetes/Metabolism Research and Reviews - October 1, 2015 Category: Endocrinology Authors: Jeremy Pettus, Tricia Santos Cavaiola, William V. Tamborlane, Steven Edelman Tags: Review Article Source Type: research
